Predictive Value of Soluble CD146 in Glioblastoma Patients - Trial NCT06001281
Access comprehensive clinical trial information for NCT06001281 through Pure Global AI's free database. This phase not specified trial is sponsored by Assistance Publique Hopitaux De Marseille and is currently Not yet recruiting. The study focuses on Glioblastoma. Target enrollment is 55 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Assistance Publique Hopitaux De Marseille
Timeline & Enrollment
N/A
Nov 01, 2023
Nov 01, 2025
Primary Outcome
correlation between soluble CD146 plasma value and patient response (RANO)
Summary
Glioblastoma is the most common malignant primary brain tumor with poor prognosis because of
 its diffusive and infiltrative nature. The FDA approved the use of the anti-VEGF antibody
 bevacizumab in recurrent GBM. However, resistance to this anti-angiogenic reagent is frequent
 and fails to enhance patients' overall survival. The investigators previously identified one
 novel mechanism responsible for bevacizumab-resistance in CD146-positive glioblastoma
 (Joshkon et al. Acta Neuropathol Commun, 2022).
 
 Now, the investigators objective is to prospectively monitor the soluble CD146 value in
 plasma from patients treated by bevacizumab for recurrent glioblastoma.
 
 The investigators will collect plasma at baseline, before the first bevacizumab
 administration, before the second administration, at the time of first MRI evaluation and at
 progression. Plasma CD146 value will be analyzed by ELISA.
 
 The investigators expect to confirm the correlation between soluble CD146 value in plasma and
 patient response to bevacizumab.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06001281
Non-Device Trial